BACKGROUND: To report and compare personal experience with international literature on uterine sarcomas. METHODS: 17 cases of uterine sarcomas diagnosed during seven years in our Institute, have been clinically histopathologically, prognostically and therapeutically analyzed. RESULTS: 10 cases of LMS, 6 of MMT, and 1 of ESS have been found. Women affected were mostly 42 to 84 years old. Most of the youngest patients were affected by LMS, while the oldest by MMT. Almost all of them were in menopause and pluriparae. The symptomatology consisted mainly of vaginal bleeding (58.9%). The diagnosis was preoperative for MMT and ESS; in 8 cases it was adopted for stage I, surgery and RT for stage II, surgery, RT and chemotherapy for a woman of stage III, and for the last two surgery and chemotherapy. The patients of stage III and IV survived respectively 8 and 10 months; three patients in stage I still have a 5 years survival and the other are still in follow-up. CONCLUSION: This work is a clinical contribution since the rarity of these neoplasms does not allow the standardization of a diagnostical and therapeutical iter and consequently the improvement of prognosis.
[Clinical experience with uterine sarcoma]. FT Esperienza clinica sui sarcomi uterini
LOIZZI, VERA;CARRIERO, Carmine;
1998-01-01
Abstract
BACKGROUND: To report and compare personal experience with international literature on uterine sarcomas. METHODS: 17 cases of uterine sarcomas diagnosed during seven years in our Institute, have been clinically histopathologically, prognostically and therapeutically analyzed. RESULTS: 10 cases of LMS, 6 of MMT, and 1 of ESS have been found. Women affected were mostly 42 to 84 years old. Most of the youngest patients were affected by LMS, while the oldest by MMT. Almost all of them were in menopause and pluriparae. The symptomatology consisted mainly of vaginal bleeding (58.9%). The diagnosis was preoperative for MMT and ESS; in 8 cases it was adopted for stage I, surgery and RT for stage II, surgery, RT and chemotherapy for a woman of stage III, and for the last two surgery and chemotherapy. The patients of stage III and IV survived respectively 8 and 10 months; three patients in stage I still have a 5 years survival and the other are still in follow-up. CONCLUSION: This work is a clinical contribution since the rarity of these neoplasms does not allow the standardization of a diagnostical and therapeutical iter and consequently the improvement of prognosis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
